Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2025European Journal of Clinical Investigation

Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

NNNadim NasrallahMAMichelle B. AtallahTHTarek Harb

Discussion

Loading...

Member takes

Overview

The findings demonstrate elevated lipoprotein(a) elevates risks of coronary artery disease and myocardial infarction, suggesting targeted therapeutic strategies.

Key Points

  • Elevated lipoprotein(a) levels notably increase the risk of coronary artery disease and myocardial infarction incidence.
  • One-time lipoprotein(a) measurement is recommended for all adults, according to current guidelines.
  • Novel agents to lower lipoprotein(a) levels show promise in phase 2 trials, highlighting the need for further investigation.
  • Elevated lipoprotein(a) can prompt more intense risk factor modification and cascade testing in families with affected individuals.

Cite This Study

Nasrallah et al. (2025) studied this question.

synapsesocial.com/papers/68e25559d6d66a53c24751bchttps://doi.org/10.1111/eci.70127
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lipoprotein a: what clinicians need to know2025 · 1 citations
  2. 2Lp(a) in the Horizon of Diagnostics and Therapy2025
  3. 3Age-Dependent Clinical Relevance of Lipoprotein(a): A Comprehensive Review from Childhood to Adulthood2025 · 4 citations
  4. 4Age – Dependent Clinical Relevance of Lipoprotein(a): A Comprehensive Review from Childhood to Adulthood2025
  5. 5Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications2025